Australia's most trusted
source of pharma news
Monday, 02 February 2026
Posted 2 February 2026 AM
The TGA has approved Gilead’s oral primary biliary cholangitis (PBC) treatment Livdelzi after a year-long review, setting the drug up for a PBAC recommendation.
Livdelzi was accepted for review by the TGA in January 2025 and deferred by the PBAC in July, with the committee noting it “was of a mind to recommend seladelpar [Livdelzi], pending advice from the Therapeutic Goods Administration Delegate”. The PBAC revealed on Friday that it has recommended Livdelzi.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.